Revision 1

Phospho-p53 (Ser46) Antibody

#2521 Store at -20C

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:
W, IP, IF-IC, FC-FP	H Mk	Endogenous	53	Rabbit

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:100
Immunofluorescence (Immunocytochemistry)	1:50
Flow Cytometry (Fixed/Permeabilized)	1:100

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

Phospho-p53 (Ser46) Antibody detects endogenous levels of p53 only when phosphorylated at serine 46. The antibody does not cross-react with p53 phosphorylated at other sites.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Ser46 of human p53. Antibodies are purified by protein A and peptide affinity chromatography.

Background

The p53 tumor suppressor protein plays a major role in cellular response to DNA damage and other genomic aberrations. Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis (1). p53 is phosphorylated at multiple sites *in vivo* and by several different protein kinases *in vitro* (2,3). DNA damage induces phosphorylation of p53 at Ser15 and Ser20 and leads to a reduced interaction between p53 and its negative regulator, the oncoprotein MDM2 (4). MDM2 inhibits p53 accumulation by targeting it for ubiquitination and proteasomal degradation (5,6). p53 can be phosphorylated by ATM, ATR, and DNA-PK at Ser15 and Ser37. Phosphorylation impairs the ability of MDM2 to bind p53, promoting both the accumulation and activation of p53 in response to DNA damage (4,7). Chk2 and Chk1 can phosphorylate p53 at Ser20, enhancing its tetramerization, stability, and activity (8,9). p53 is phosphorylated at Ser392 *in vivo* (10,11) and by CAK *in vitro* (11). Phosphorylation of p53 at Ser392 is increased in human tumors (12) and has been reported to influence the growth suppressor function, DNA binding, and transcriptional activation of p53 (10,13,14). p53 is phosphorylated at Ser6 and Ser9 by CK1δ and CK1ε both *in vitro* and *in vivo* (13,15). Phosphorylation of p53 at Ser46 regulates the ability of p53 to induce apoptosis (16). Acetylation of p53 is mediated by p300 and CBP acetyltransferases. Inhibition of deacetylation suppressing MDM2 from recruiting HDAC1 complex by p19 (ARF) stabilizes p53. Acetylation appears to play a positive role in the accumulation of p53 protein in stress response (17). Following DNA damage, human p53 becomes acetylated at Lys382 (Lys379 in mouse) *in vivo* to enhance p53-DNA binding (18). Deacetylation of p53 occurs through interaction with the SIRT1 protein, a deacetylase that may be involved in cellular aging and the DNA damage response (19). Homeodomain-interacting protein kinase 2 (HIPK2) Phosphorylates Ser46 off p53 in vitro and in vivo (17,18), and p38 can phosphorylate this site in vitro (19).

Background References

1. Levine, A.J. (1997) *Cell* 88, 323-31.
2. Meek, D.W. (1994) *Semin Cancer Biol* 5, 203-10.
3. Milczarek, G.J. et al. (1997) *Life Sci* 60, 1-11.
4. Shieh, S.Y. et al. (1997) *Cell* 91, 325-34.
5. Chehab, N.H. et al. (1999) *Proc Natl Acad Sci U S A* 96, 13777-82.
6. Honda, R. et al. (1997) *FEBS Lett* 420, 25-7.
7. Tibbetts, R.S. et al. (1999) *Genes Dev* 13, 152-7.
8. Shieh, S.Y. et al. (1999) *EMBO J* 18, 1815-23.
9. Hirao, A. et al. (2000) *Science* 287, 1824-7.
10. Hao, M. et al. (1996) *J Biol Chem* 271, 29380-5.
11. Lu, H. et al. (1997) *Mol Cell Biol* 17, 5923-34.
12. Ullrich, S.J. et al. (1993) *Proc Natl Acad Sci U S A* 90, 5954-8.
13. Kohn, K.W. (1999) *Mol Biol Cell* 10, 2703-34.
14. Lohrum, M. and Scheidtmann, K.H. (1996) *Oncogene* 13, 2527-39.
15. Knippschild, U. et al. (1997) *Oncogene* 15, 1727-36.
16. Oda, K. et al. (2000) *Cell* 102, 849-62.

17. Ito, A. et al. (2001) *EMBO J* 20, 1331-40.
18. Sakaguchi, K. et al. (1998) *Genes Dev* 12, 2831-41.
19. Solomon, J.M. et al. (2006) *Mol Cell Biol* 26, 28-38.
20. D'Orazi, G. et al. (2002) *Nat. Cell Biol.* 4, 11-19.
21. Hofmann, T. G. et al. (2002) *Nat. Cell Biol.* 4, 1-10.
22. Bulavin, D. V. et al. (1999) *EMBO J.* 18, 6845-6854.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation **IF-IC:** Immunofluorescence (Immunocytochemistry) **FC-FP:** Flow Cytometry (Fixed/Permeabilized)

Cross-Reactivity Key

H: Human **Mk:** Monkey

Trademarks and Patents

Limited Uses